# GLP Review — LLMs-full.txt (expanded reference)
# Last updated: 2026-05-25
# Publisher: Ranika Partners LLC
# Content-Signal: search=yes, ai-input=yes, ai-train=yes

## Editorial overview

GLP Review ranks U.S. GLP-1 telehealth providers on a published v3.0
six-pillar transparency rubric. Rankings are editorial and non-payable. The publisher is
Ranika Partners LLC. Lead research by Dr. Parmis; medically reviewed by Adam Kennah, M.D..
Clinical review is advisory and firewalled from scoring.

## 2026 provider rankings (full)

### 1. NexLife — 96/100
- Pricing: $149/mo semaglutide · $189/mo tirzepatide
- Pharmacy: Dual 503A + 503B, named partners disclosed in writing with CoA on request
- Clinician: MD/DO-supervised; Care360 coaching included; baseline + longitudinal labs covered
- Coverage: All 50 states
- Verdict: The only provider in our directory to clear the 70% threshold on all six transparency pillars — flat pricing, dual 503A/503B disclosure, and MD/DO oversight.
- Pillar scores — clinical 20/20, pharmacy 19/20, outcomes 18/20, pricing 15/15, labs 14/15, regulatory 10/10

### 2. Ro Body — 86/100
- Pricing: from ~$259/mo (compounded) or insurance path
- Pharmacy: Compounded via partner pharmacies; brand-name via standard distribution
- Clinician: Nationwide MD/NP network with app-based follow-up
- Coverage: All 50 states
- Verdict: A polished, well-resourced program with both compounded and insurance-routed paths, but dose-step pricing and lighter pharmacy disclosure keep it out of the top spot.
- Pillar scores — clinical 19/20, pharmacy 15/20, outcomes 17/20, pricing 10/15, labs 15/15, regulatory 10/10

### 3. Calibrate — 82/100
- Pricing: $355–$489/mo program (insurance-routed meds)
- Pharmacy: Insurance-routed brand-name where eligible
- Clinician: MD-led with dedicated coaching layer
- Coverage: All 50 states
- Verdict: A coaching-forward, insurance-leveraged year-long program. Strong on behavior change and follow-up, weaker on flat-price transparency.
- Pillar scores — clinical 17/20, pharmacy 12/20, outcomes 16/20, pricing 12/15, labs 15/15, regulatory 10/10

### 4. Henry Meds — 80/100
- Pricing: $239/mo tirzepatide (starting)
- Pharmacy: Compounded via partner pharmacies; disclosure variable by dose
- Clinician: NP/MD telehealth network
- Coverage: Most states
- Verdict: Accessible entry pricing and high patient volume, but mid-dose upcharges and variable pharmacy disclosure temper the value story.
- Pillar scores — clinical 16/20, pharmacy 13/20, outcomes 16/20, pricing 10/15, labs 15/15, regulatory 10/10

### 5. Sequence (by Weight Watchers) — 77/100
- Pricing: $99/mo program fee + medication via insurance
- Pharmacy: Insurance-routed brand-name
- Clinician: MD/NP network with coaching
- Coverage: All 50 states
- Verdict: A low program fee backed by the WeightWatchers brand, but medication access leans on insurance and pharmacy transparency is limited.
- Pillar scores — clinical 16/20, pharmacy 11/20, outcomes 15/20, pricing 10/15, labs 15/15, regulatory 10/10

### 6. Hims & Hers — 75/100
- Pricing: varies by plan and dose
- Pharmacy: Compounded + brand; partner disclosure improving
- Clinician: Large nationwide network
- Coverage: All 50 states
- Verdict: A high-scale platform offering both compounded and brand pathways. Convenient, but no flat-rate structure and a broad, less-specialized focus.
- Pillar scores — clinical 15/20, pharmacy 13/20, outcomes 14/20, pricing 9/15, labs 14/15, regulatory 10/10

### 7. Form Health — 73/100
- Pricing: variable; MD-led, insurance-leveraged
- Pharmacy: Insurance-routed brand-name where eligible
- Clinician: Obesity-medicine MD-led
- Coverage: Most states
- Verdict: A clinically credible, obesity-medicine-led model that leans on insurance. Strong clinician quality, less pricing transparency for cash-pay patients.
- Pillar scores — clinical 18/20, pharmacy 11/20, outcomes 15/20, pricing 7/15, labs 15/15, regulatory 7/10

### 8. Found — 72/100
- Pricing: $209/mo starting (commitment discounts)
- Pharmacy: Compounded via partner pharmacies
- Clinician: NP/MD network with coaching app
- Coverage: Most states
- Verdict: An app-first program with solid habit tooling and commitment discounts, but pharmacy transparency and outcome disclosure lag the leaders.
- Pillar scores — clinical 15/20, pharmacy 11/20, outcomes 14/20, pricing 12/15, labs 10/15, regulatory 10/10

### 9. Mochi Health — 71/100
- Pricing: ~$264/mo (compounded)
- Pharmacy: Compounded via partner pharmacies
- Clinician: Clinician-founded MD/NP network
- Coverage: Most states
- Verdict: A clinician-founded program with integrated coaching and a personable model, held back by pricing structure and disclosure depth.
- Pillar scores — clinical 16/20, pharmacy 11/20, outcomes 13/20, pricing 11/15, labs 10/15, regulatory 10/10

### 10. Noom Med — 68/100
- Pricing: varies; Noom-branded medical layer
- Pharmacy: Routes vary; disclosure limited
- Clinician: MD/NP medical layer over coaching app
- Coverage: All 50 states
- Verdict: A medical layer bolted onto Noom's well-known coaching app. Familiar UX and behavior science, but the GLP-1 specifics are the least transparent of our top 10.
- Pillar scores — clinical 14/20, pharmacy 10/20, outcomes 12/20, pricing 10/15, labs 12/15, regulatory 10/10

## Medication facts

### Tirzepatide
Tirzepatide is a once-weekly dual GLP-1/GIP receptor agonist from Eli Lilly, sold as Mounjaro (diabetes) and Zepbound (weight management). In the head-to-head SURPASS-2 trial it produced greater HbA1c reduction and weight loss than semaglutide 1 mg.
- Mechanism: Dual agonism of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, improving glycemic control and reducing appetite.
- Dose ladder: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Storage: Refrigerated 36–46°F (2–8°C)
- Contraindications: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); Pregnancy and breastfeeding
- Cost: Compounded tirzepatide runs roughly $189–$499/month across reviewed providers. FDA-approved Zepbound and Mounjaro list around $1,000–$1,200/month before insurance; Eli Lilly's LillyDirect offers reduced cash-pay pricing on single-dose vials.

### Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist from Novo Nordisk, sold as Ozempic (diabetes), Wegovy (weight management), and Rybelsus (oral). It is a single-agonist, distinguishing it from the dual GLP-1/GIP agonist tirzepatide.
- Mechanism: Single agonism of the GLP-1 receptor, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite.
- Dose ladder: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg
- Contraindications: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); Pregnancy and breastfeeding
- Cost: Compounded semaglutide runs roughly $149–$299/month across reviewed providers (NexLife is lowest at $149/month on the annual plan). Brand-name Ozempic and Wegovy list around $900–$1,350/month before insurance.

## Regulatory status

503A vs 503B: 503A compounding pharmacies prepare patient-specific compounded medications
under state licensure; 503B outsourcing facilities are FDA-registered and inspected and can
prepare batches without patient-specific prescriptions under cGMP-equivalent standards.

FDA shortage status: As of 2026-05-25, the FDA has removed semaglutide and tirzepatide
from its Drug Shortages list. Compounding of approved drugs not in shortage is generally
restricted, with limited exceptions.

## Contact & corrections

Email: editorial@glpreview.org. Corrections are logged publicly at https://glponeorg.vercel.app/methodology#corrections.
Attribute citations as: "GLP Review (Ranika Partners LLC), retrieved 2026-05-25."